ImmunoGen is known for its designated disease therapy, Elahere, which is endorsed for patients with fallopian tube malignant growth and essential peritoneal malignant growth. In late November, AbbVie (ABBV) declared its $10.1 billion intend to purchase ImmunoGen.
In the second from last quarter, Elahere deals were $105.2 million, representing the overwhelming majority of $113.4 million in income. Revenue easily exceeded the $103.7 million that was predicted by FactSet-polled analysts. ImmunoGen likewise announced its first benefit in quite a while.
AbbVie says ImmunoGen’s late-stage testing endeavors for Elahere give it an amazing chance to move into arriving at patients prior in the treatment worldview.